China’s CDE Survey Shows Oncology, Diabetes and Cardiovascular Studies Lead Drug R&D Efforts
This article was originally published in PharmAsia News
Executive Summary
MNCs and small biotech firms in China are more focused on oncology, while domestic companies have more R&D projects on anti-inflammatory drugs and anti-infectives, according to a survey conducted by China’s drug review body.